Global Pandemic Preparedness Summit & CEPI Replenishment

Associations representing vaccine manufacturers in the developing and developed world, as well as the broader biotech and biopharmaceutical industry (ABPI, BIA, BIO and the DCVMN and IFPMA) have released a joint Statement on 8 March 2022 on the occasion of the Global Pandemic preparedness Summit.

IFPMA and ABPI member companies’ commitments are listed below:

AstraZeneca

The story of the vaccine is one of unprecedented collaboration. Our landmark partnership with Oxford University enabled us to pool world-renowned expertise in vaccinology with large scale manufacturing in the very early stages of the pandemic. The result was that through a network of 25 partners, we were able to accelerate production of the vaccine over the course of a few months, a process that normally takes years. This provides a template for the future and demonstrates the importance of public private investment in creating sustainable regional manufacturing operations as well as the need for a simplified regulatory environment. The pandemic has also spurred phenomenal scientific innovation. At AstraZeneca, alongside the vaccine, we have developed a long-acting antibody COVID-19 therapy to protect vulnerable populations. These COVID-19 medicines form a central part of our new Vaccines and Immune Therapies unit, which is focused on finding ways to address infectious diseases. This unit builds on everything we have learnt from our response to Covid and put us in a strong position to tackle any future pandemics.

GSK

GSK has advocated for CEPI since its inception in 2017, and we continue to support CEPI’s role in the global health architecture.

GSK was an active contributor to the UK G7 Pandemic Preparedness Partnership (PPP) and 100-days mission.

GSK has maintained pandemic readiness with our supply of pandemic adjuvanted influenza vaccines and activated our adjuvant supply for coronavirus partnerships. We are in the final stages with several partners, including Medicago, Sanofi and CEPI supported SK Bioscience, on the development and licensure of 3 protein-based COVID-19 vaccines using GSK’s pandemic adjuvant. In addition, our monoclonal antibody sotrivimab, developed with Vir, was approved under EUA in 2021.

We intend to extend our pandemic readiness with a broad array of technologies. We will also look to support skills development and R&D programs in Africa by leveraging our global health partnerships and longstanding experience in manufacturing and clinical research in Africa, notably our Malaria and TB vaccine trials and phase IV collaborations in sub-Saharan Africa.
Johnson & Johnson

Johnson & Johnson strongly supports the goals of the UK’s Global Pandemic Preparedness Summit and the ambitions of the 100 Days Mission. Over the past 25 years we have made substantial investments in cutting-edge R&D capabilities and platform technologies to bring forward vaccines and therapeutics that help prevent disease, save lives, and combat epidemics, as shown by our accelerated Ebola and COVID-19 vaccine programmes. We have supported CEPI since its inception and look forward to continuing our work together. Effective collaboration is central to improved global health security and the successful protection of vulnerable communities from urgent threats like COVID-19 and persistent challenges, like HIV and tuberculosis. These collaborations should be the new normal and support improvements in R&D, clinical trials infrastructure, global regulatory frameworks, and digital technologies. As manufacturing capacity expands, life-course immunisation will be a vital component of improved readiness to maintain vaccine production between pandemics that will be the basis for scale-up in an emergency. We are committed to a world in which epidemics and pandemics no longer threaten humanity.

Novo Nordisk Foundation

Strengthening epidemic preparedness is a key pillar in the Novo Nordisk Foundation’s (NNF) forthcoming 2030 strategy. A broad portfolio of translational research activities are envisaged, and initial mission-driven initiatives will focus on developing new anti-viral drugs, or new vaccines against viral and bacterial targets. With regards to the latter, the NNF has recently begun developing plans for a Center for Infectious Disease Research and Vaccine Design in Denmark. The ambition for this initiative is to establish a critical mass that conducts discovery, translational research and clinical trials on vaccines against diverse respiratory pathogens that have epidemic potential or promote the spread of antimicrobial resistance.

Pfizer

The pandemic taught us that we can accomplish great things when we are united by a common purpose. The virus knows no geographic borders. It doesn’t discriminate based on race, religion, gender, financial condition or political affiliation. So, to defeat it, we need to be united.

That’s why we focused our efforts and mobilized our resources to forge partnerships with industry peers, health authorities and experts around the world as we worked to protect the health and safety of our communities, and find medical and scientific solutions to this crisis.

The dedication and accomplishments of scientists and partners is nothing short of inspiring. And, every area of Pfizer has rapidly transformed the way we work, proving in many instances that the impossible is indeed possible. We are all forever changed by what the crisis has demanded from each of us. The sense of purpose, spirit of collaboration, degree of confidence and deeper pride in our work will extend well beyond the pandemic, as serving the needs of patients around the world is what we do every day.
Sanofi commits to playing an important role in responding to future pandemics via three key levers. First, innovation through investment in state-of-the-art mRNA technology with the launch of Centers of Excellence to accelerate end-to-end R&D of next-generation vaccines and drive a new era of response capability. Second, taking our diversified industrial footprint to the next level through Evolutive Vaccine Facilities that are setting a new standard for biologics manufacturing flexibility and speed. Third, public – private partnership excellence in respiratory disease surveillance through the Global Influenza Hospital Surveillance Network, over 100 hospitals in 20 countries collecting and sharing clinical, virological and virus genome sequencing data. Leveraging existing domestic assets and artificial intelligence expertise, this resilient network is set to expand for pandemic preparedness. A reminder for all: success of a pandemic response through these investments requires unencumbered access to pathogens to be able to be prepared and respond.